NO20044963L - Tricyclic thrombin receptor antagonists - Google Patents

Tricyclic thrombin receptor antagonists

Info

Publication number: NO20044963L
Authority: NO; Norway
Prior art keywords: receptor antagonists; thrombin receptor; tricyclic thrombin; tricyclic; antagonists
Prior art date: 2002-04-16

Application number

NO20044963A

Other languages

Norwegian (no)

Other versions

NO330500B1 (en

Inventor

William J Greenlee

Samuel Chackalamannil

Yuguang Wang

Yan Xia

Martin C Clasby

Mariappan Chelliah

Enrico P Veltri

Wenxue Wu

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-16

Filing date

2004-11-15

Publication date

2004-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20044963(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-11-15 Application filed by Schering Corp filed Critical Schering Corp

2004-11-15 Publication of NO20044963L publication Critical patent/NO20044963L/en

2011-05-02 Publication of NO330500B1 publication Critical patent/NO330500B1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20044963A 2002-04-16 2004-11-15 Tricyclic thrombin receptor antagonists NO330500B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37307202P	2002-04-16	2002-04-16
PCT/US2003/011510 WO2003089428A1 (en)	2002-04-16	2003-04-14	Tricyclic thrombin receptor antagonists

Publications (2)

Publication Number	Publication Date
NO20044963L true NO20044963L (en)	2004-11-15
NO330500B1 NO330500B1 (en)	2011-05-02

Family

ID=29250954

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20044963A NO330500B1 (en)	2002-04-16	2004-11-15	Tricyclic thrombin receptor antagonists
NO2015016C NO2015016I1 (en)	2002-04-16	2015-07-09	Vorapaxar, or a pharmaceutically acceptable salt or solvate thereof

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2015016C NO2015016I1 (en)	2002-04-16	2015-07-09	Vorapaxar, or a pharmaceutically acceptable salt or solvate thereof

Country Status (34)

Country	Link
US (3)	US7304078B2 (en)
EP (5)	EP1495018B3 (en)
JP (2)	JP4558331B2 (en)
KR (1)	KR101026929B1 (en)
CN (1)	CN1659162B (en)
AR (1)	AR039570A1 (en)
AT (3)	ATE455774T1 (en)
AU (1)	AU2003221932B2 (en)
BR (1)	BRPI0309309B8 (en)
CA (1)	CA2482858C (en)
CY (3)	CY1107184T1 (en)
DE (3)	DE60317493T3 (en)
DK (2)	DK2065384T3 (en)
EC (1)	ECSP045368A (en)
ES (3)	ES2357876T3 (en)
FR (1)	FR15C0047I2 (en)
HK (3)	HK1070887A1 (en)
IL (1)	IL164585A (en)
LT (1)	LTC1495018I2 (en)
LU (1)	LU92759I2 (en)
MX (1)	MXPA04010308A (en)
MY (1)	MY144040A (en)
NL (1)	NL300746I1 (en)
NO (2)	NO330500B1 (en)
NZ (2)	NZ535880A (en)
PE (1)	PE20040412A1 (en)
PL (1)	PL214718B1 (en)
PT (2)	PT2065384E (en)
RU (2)	RU2329264C9 (en)
SG (1)	SG164279A1 (en)
SI (2)	SI2065384T1 (en)
TW (1)	TWI343919B (en)
WO (1)	WO2003089428A1 (en)
ZA (1)	ZA200408342B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6346510B1 (en)	1995-10-23	2002-02-12	The Children's Medical Center Corporation	Therapeutic antiangiogenic endostatin compositions
US7488742B2 (en) *	2000-06-15	2009-02-10	Schering Corporation	Thrombin receptor antagonists
US7235567B2 (en) *	2000-06-15	2007-06-26	Schering Corporation	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) *	2000-06-15	2004-09-30	Samuel Chackalamannil	Methods of use of thrombin receptor antagonists
MXPA06013903A (en) *	2004-05-28	2007-01-26	Schering Corp	Constrained himbacine analogs as thrombin receptor antagonists.
AU2005294265A1 (en) *	2004-10-06	2006-04-20	University Of Rochester	Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
US7772276B2 (en) *	2005-01-14	2010-08-10	Schering Corporation	Exo-selective synthesis of himbacine analogs
AR052870A1 (en) *	2005-01-14	2007-04-11	Schering Corp	SYNTHESIS OF ANALOGS OF HIMBACINA
CA2594742A1 (en) *	2005-01-14	2006-07-20	Schering Corporation	Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
DE602006012450D1 (en) *	2005-01-14	2010-04-08	Schering Corp	EXO- AND DIASTEREOSELECTIVE SYNTHESIS OF HIMBACIN ANALOGUE
US7541471B2 (en) *	2005-01-14	2009-06-02	Schering Corporation	Synthesis of himbacine analogs
TWI316937B (en)	2005-03-31	2009-11-11	Schering Corp	Spirocyclic thrombin receptor antagonists
US20070219154A1 (en) *	2005-12-20	2007-09-20	Suxing Liu	Methods for preventing and/or treating a cell proliferative disorder
JP2009521472A (en) *	2005-12-22	2009-06-04	シェーリングコーポレイション	Thrombin receptor antagonist as prevention of complications of cardiopulmonary surgery
PE20080183A1 (en) *	2006-04-06	2008-03-10	Schering Corp	TRA COMBINATION THERAPIES
EP2007755B1 (en) *	2006-04-13	2012-06-27	Schering Corporation	Fused ring thrombin receptor antagonists
JP2009542662A (en) *	2006-06-29	2009-12-03	シェーリングコーポレイション	Substituted bicyclic and tricyclic thrombin receptor antagonists
AR061727A1 (en) *	2006-06-30	2008-09-17	Schering Corp	DIETILE SYNTHESIS [[5- (3-FLUOROPHENYL) -PIRIDIN -2IL] METHYL] PHOSPHONATE
TWI367112B (en) *	2006-06-30	2012-07-01	Schering Corp	Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (en)	2006-08-02	2008-02-07	Sanofi-Aventis	Imino-imidazo-pyridine derivatives with antithrombotic activity
TWI343262B (en) *	2006-09-26	2011-06-11	Schering Corp	Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
AU2007305269A1 (en) *	2006-10-04	2008-04-10	Schering Corporation	Bicyclic and tricyclic derivatives as thrombin receptor antagonists
AR063095A1 (en) *	2006-10-04	2008-12-30	Schering Corp	THROMBINE RECEIVER ANTAGONISTS BASED ON THE MODIFIED TRICYCLE UNIT OF HIMBACINE
EP2120879A2 (en) *	2006-12-22	2009-11-25	Schering Corporation	Disintegration promoters in solid dose wet granulation formulations
BRPI0809095A2 (en) *	2007-03-23	2014-09-09	Schering Corp	ADVERSE EVENT REDUCTION AFTER PERCUTANEOUS INTERVENTION THROUGH USE OF A THROMBINE RECEIVER ANTAGONIST
MY152040A (en)	2008-02-05	2014-08-15	Sanofi Aventis	Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
PL2240486T3 (en)	2008-02-05	2016-02-29	Sanofi Sa	Triazolium salts as par1 inhibitors, their manufacture and their application as medicine
WO2009124103A2 (en) *	2008-04-02	2009-10-08	Schering Corporation	Combination therapies comprising par1 antagonists with par4 antagonists
TW201008930A (en)	2008-05-19	2010-03-01	Schering Corp	Heterocyclic compounds as factor IXa inhibitors
WO2010141525A1 (en)	2009-06-04	2010-12-09	Schering Corporation	Active metabolite of a thrombin receptor antagonist
MX2011013091A (en)	2009-06-08	2012-01-12	Schering Corp	A thrombin receptor antagonist and clopidogrel fixed dose tablet.
US8609676B2 (en)	2009-08-04	2013-12-17	Merck Sharp & Dohme, Corp.	4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
ES2532902T3 (en)	2010-04-16	2015-04-01	Sanofi	Tricyclic pyridyl vinyl pyrroles as inhibitors of PAR1
EP2558462B1 (en)	2010-04-16	2014-10-22	Sanofi	Pyridyl-vinyl-pyrazolo-chinolines as PAR1 inhibitors
KR101303348B1 (en)	2010-06-25	2013-09-03	한국화학연구원	[6 + 5] conjugated bicycle, a thrombin receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same
EP2822557B1 (en)	2012-03-06	2017-08-23	Merck Sharp & Dohme Corp.	Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
EP3024550A4 (en)	2013-07-22	2016-12-07	Merck Sharp & Dohme	CO-CRYSTAL OF VORAPAXAR PAR-1 RECEPTOR ANTAGONIST AND ASPIRINE
EP3035928B1 (en)	2013-08-22	2023-10-18	Merck Sharp & Dohme LLC	3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
EP3035929B1 (en)	2013-08-22	2024-07-03	Merck Sharp & Dohme LLC	7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
WO2015026685A1 (en) *	2013-08-22	2015-02-26	Merck Sharp & Dohme Corp.	7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
FR3014693B1 (en)	2013-12-16	2016-01-08	Pf Medicament	USE OF 3- (2-CHLORO-PHENYL) -1- [4- (4-FLUORO-BENZYL) -PIPERAZIN-1-YL] -PROPENONE FOR THE PREVENTION AND / OR TREATMENT OF PELVI-PERINEAL FUNCTIONAL PATHOLOGIES
US9969724B2 (en)	2014-04-16	2018-05-15	Merck Sharp & Dohme Corp.	Factor IXa inhibitors
DE102014108210A1 (en)	2014-06-11	2015-12-17	Dietrich Gulba	rodenticide
CN105985303B (en) *	2015-02-13	2020-08-14	上海彩迩文生化科技有限公司	Preparation method of anticoagulant, intermediate and preparation method thereof
CN106478608A (en) *	2015-09-01	2017-03-08	博瑞生物医药（苏州）股份有限公司	The crystalline polymorph of the husky sulfate of Walla handkerchief
CN106749201A (en) *	2015-11-25	2017-05-31	博瑞生物医药（苏州）股份有限公司	A kind of preparation method of Walla handkerchief sand and its intermediate
TR201601548A2 (en) *	2016-02-05	2018-03-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A PHARMACEUTICAL COMPOSITION OF VORAPAKSAR AND METOPROLOL
WO2017134200A1 (en) *	2016-02-05	2017-08-10	Sanovel Ilac Sanayi Ve Ticaret A.S.	A novel pharmaceutical composition of vorapaxar and metoprolol
TW201738221A (en) *	2016-04-22	2017-11-01	Jiangsu Tasly Diyi Pharmaceutical Co Ltd	New himbacine analogue and uses thereof in medicines
CN106236779A (en) *	2016-08-22	2016-12-21	孔五	A kind of preparation method of Cord blood platelet rich plasma PRP
FR3090317B1 (en)	2018-12-19	2021-05-07	Cvasthera	USE OF A PAR-1 ANTAGONIST FOR THE TREATMENT OF CHRONIC INFLAMMATORY INTESTINAL DISEASE
CN110407819B (en) *	2019-08-02	2020-06-26	牡丹江医学院	A Thrombin Receptor Antagonist as Prevention of Surgical Complications
US20210113536A1 (en) *	2019-10-21	2021-04-22	United States Government as Represented by the Department of Veteran Affairs	Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (en)	2020-04-08	2023-04-14	Cvasthera	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
EP4185587A1 (en)	2020-07-22	2023-05-31	JANSSEN Pharmaceutica NV	Compounds useful as factor xia inhibitors
US11814364B2 (en)	2021-03-18	2023-11-14	Janssen Pharmaceutica Nv	Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en)	2021-03-18	2023-12-19	Janssen Pharmaceutica Nv	Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en)	2021-03-18	2024-03-05	Janssen Pharmaceutica Nv	Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (en)	2021-04-06	2022-10-12	BIORoxx GmbH	Use of anticoagulant active compounds as rodenticide
US11897880B2 (en)	2021-04-30	2024-02-13	Janssen Pharmaceutica Nv	7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en)	2021-07-22	2024-04-16	Janssen Pharmaceutica Nv	Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (en)	2022-04-08	2023-10-13	Cvasthera	PHARMACEUTICAL COMPOSITION BASED ON VORAPAXAR AND ITS USE FOR THE TREATMENT OF INFLAMMATORY INTESTINAL DISEASES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2623810B2 (en)	1987-02-17	1992-01-24	Sanofi Sa	ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
IL106197A (en)	1992-07-30	1999-11-30	Cor Therapeutics Inc	Thrombin receptor antagonists and pharmaceutical compositions comprising them
US5576328A (en)	1994-01-31	1996-11-19	Elf Sanofi	Method for the secondary prevention of ischemic events
US6063847A (en) *	1997-11-25	2000-05-16	Schering Corporation	Thrombin receptor antagonists
ZA9810685B (en) *	1997-11-25	1999-12-23	Schering Corp	Thrombin receptor antagonists.
FR2779726B1 (en)	1998-06-15	2001-05-18	Sanofi Sa	POLYMORPHIC FORM OF CLOPIDOGREL HYDROGENOSULFATE
US7488742B2 (en)	2000-06-15	2009-02-10	Schering Corporation	Thrombin receptor antagonists
US20040192753A1 (en)	2000-06-15	2004-09-30	Samuel Chackalamannil	Methods of use of thrombin receptor antagonists
EP2301930B1 (en)	2000-06-15	2016-01-06	Merck Sharp & Dohme Corp.	Derivatives of hexahydrobenzofuranone useful for the treatment of (inter alia) auto-immune or inflammatory disorders
PE20030808A1 (en)	2001-10-18	2003-09-22	Schering Corp	HETEROCYCLIC TRICYCLE DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS

2003
- 2003-04-14 AT AT07016461T patent/ATE455774T1/en not_active IP Right Cessation
- 2003-04-14 PL PL373332A patent/PL214718B1/en unknown
- 2003-04-14 AU AU2003221932A patent/AU2003221932B2/en not_active Ceased
- 2003-04-14 WO PCT/US2003/011510 patent/WO2003089428A1/en active Application Filing
- 2003-04-14 BR BRPI0309309A patent/BRPI0309309B8/en not_active IP Right Cessation
- 2003-04-14 PE PE2003000375A patent/PE20040412A1/en active IP Right Grant
- 2003-04-14 PT PT09150995T patent/PT2065384E/en unknown
- 2003-04-14 JP JP2003586149A patent/JP4558331B2/en not_active Expired - Fee Related
- 2003-04-14 MY MYPI20031400A patent/MY144040A/en unknown
- 2003-04-14 SG SG200607217-7A patent/SG164279A1/en unknown
- 2003-04-14 SI SI200331969T patent/SI2065384T1/en unknown
- 2003-04-14 ES ES09150995T patent/ES2357876T3/en not_active Expired - Lifetime
- 2003-04-14 ES ES03718393T patent/ES2297150T7/en active Active
- 2003-04-14 NZ NZ535880A patent/NZ535880A/en not_active IP Right Cessation
- 2003-04-14 PT PT03718393T patent/PT1495018E/en unknown
- 2003-04-14 SI SI200331110T patent/SI1495018T1/en unknown
- 2003-04-14 EP EP03718393A patent/EP1495018B3/en not_active Expired - Lifetime
- 2003-04-14 AT AT03718393T patent/ATE378330T1/en active
- 2003-04-14 CN CN038131129A patent/CN1659162B/en not_active Expired - Fee Related
- 2003-04-14 RU RU2004133375/04A patent/RU2329264C9/en active
- 2003-04-14 DK DK09150995.0T patent/DK2065384T3/en active
- 2003-04-14 EP EP07016461A patent/EP1860106B1/en not_active Expired - Lifetime
- 2003-04-14 AT AT09150995T patent/ATE494284T1/en active
- 2003-04-14 DK DK03718393T patent/DK1495018T3/en active
- 2003-04-14 DE DE60317493.0T patent/DE60317493T3/en not_active Expired - Lifetime
- 2003-04-14 EP EP09150996A patent/EP2062890B1/en not_active Expired - Lifetime
- 2003-04-14 MX MXPA04010308A patent/MXPA04010308A/en active IP Right Grant
- 2003-04-14 US US10/412,982 patent/US7304078B2/en active Active
- 2003-04-14 KR KR1020047016409A patent/KR101026929B1/en active IP Right Grant
- 2003-04-14 CA CA2482858A patent/CA2482858C/en not_active Expired - Lifetime
- 2003-04-14 DE DE60335679T patent/DE60335679D1/en not_active Expired - Lifetime
- 2003-04-14 DE DE60331114T patent/DE60331114D1/en not_active Expired - Lifetime
- 2003-04-14 NZ NZ575139A patent/NZ575139A/en not_active IP Right Cessation
- 2003-04-14 ES ES07016461T patent/ES2338171T3/en not_active Expired - Lifetime
- 2003-04-14 EP EP08012015A patent/EP1982984B1/en not_active Expired - Lifetime
- 2003-04-14 AR ARP030101302A patent/AR039570A1/en active IP Right Grant
- 2003-04-14 EP EP09150995A patent/EP2065384B1/en not_active Expired - Lifetime
- 2003-04-15 TW TW092108648A patent/TWI343919B/en not_active IP Right Cessation
2004
- 2004-10-14 ZA ZA200408342A patent/ZA200408342B/en unknown
- 2004-10-14 IL IL164585A patent/IL164585A/en active IP Right Grant
- 2004-10-15 EC EC2004005368A patent/ECSP045368A/en unknown
- 2004-11-15 NO NO20044963A patent/NO330500B1/en not_active IP Right Cessation
2005
- 2005-04-22 HK HK05103479A patent/HK1070887A1/en not_active IP Right Cessation
2007
- 2007-04-10 US US11/733,635 patent/US7713999B2/en not_active Expired - Lifetime
- 2007-07-06 US US11/774,358 patent/US20070270439A1/en not_active Abandoned
2008
- 2008-02-07 CY CY20081100152T patent/CY1107184T1/en unknown
- 2008-02-21 RU RU2008106401/04A patent/RU2008106401A/en not_active Application Discontinuation
2009
- 2009-03-23 HK HK09102736.6A patent/HK1123302A1/en not_active IP Right Cessation
- 2009-09-14 HK HK09108388.4A patent/HK1129893A1/en not_active IP Right Cessation
2010
- 2010-03-05 JP JP2010049903A patent/JP2010132710A/en not_active Withdrawn
2011
- 2011-03-30 CY CY20111100338T patent/CY1111363T1/en unknown
2015
- 2015-06-29 NL NL300746C patent/NL300746I1/nl unknown
- 2015-06-29 LU LU92759C patent/LU92759I2/en unknown
- 2015-07-01 LT LTPA2015027C patent/LTC1495018I2/en unknown
- 2015-07-03 FR FR15C0047C patent/FR15C0047I2/en active Active
- 2015-07-09 NO NO2015016C patent/NO2015016I1/en not_active IP Right Cessation
- 2015-07-10 CY CY2015029C patent/CY2015029I2/en unknown

Also Published As

Publication number	Publication date
JP2010132710A (en)	2010-06-17
DE60317493D1 (en)	2011-01-13
NL300746I2 (en)	2016-01-21
EP1982984A3 (en)	2008-10-29
ES2297150T7 (en)	2012-03-16
DE60317493T2 (en)	2008-09-18
KR101026929B1 (en)	2011-04-04
NO2015016I1 (en)	2015-07-20
EP2065384A1 (en)	2009-06-03
MY144040A (en)	2011-07-29
NL300746I1 (en)	2016-01-21
CA2482858A1 (en)	2003-10-30
US7304078B2 (en)	2007-12-04
PT2065384E (en)	2011-03-16
CY2015029I1 (en)	2016-04-13
HK1129893A1 (en)	2009-12-11
CY2015029I2 (en)	2016-04-13
DK1495018T3 (en)	2008-02-18
EP1495018B3 (en)	2011-03-16
NZ535880A (en)	2007-11-30
DE60335679D1 (en)	2011-02-17
RU2008106401A (en)	2009-08-27
ATE455774T1 (en)	2010-02-15
ZA200408342B (en)	2006-05-31
AU2003221932B2 (en)	2007-11-22
NO2015016I2 (en)	2015-07-09
MXPA04010308A (en)	2005-02-03
IL164585A (en)	2010-11-30
LTC1495018I2 (en)	2017-04-10
US20030216437A1 (en)	2003-11-20
PE20040412A1 (en)	2004-07-12
JP2005528406A (en)	2005-09-22
PL214718B1 (en)	2013-09-30
TWI343919B (en)	2011-06-21
EP1860106B1 (en)	2010-01-20
ECSP045368A (en)	2005-01-03
US20070270439A1 (en)	2007-11-22
HK1070887A1 (en)	2005-06-30
NZ575139A (en)	2010-08-27
CY1111363T1 (en)	2015-08-05
EP1495018B1 (en)	2007-11-14
PT1495018E (en)	2008-02-19
ATE494284T1 (en)	2011-01-15
BRPI0309309B8 (en)	2021-05-25
RU2329264C2 (en)	2008-07-20
AU2003221932A1 (en)	2003-11-03
BR0309309A (en)	2005-02-15
EP1982984B1 (en)	2013-02-13
DE60317493T3 (en)	2018-07-12
ES2338171T3 (en)	2010-05-04
RU2004133375A (en)	2005-07-10
EP1495018A1 (en)	2005-01-12
CN1659162B (en)	2011-08-31
FR15C0047I2 (en)	2016-05-06
PL373332A1 (en)	2005-08-22
HK1123302A1 (en)	2009-06-12
TW200404068A (en)	2004-03-16
DE60331114D1 (en)	2010-03-11
WO2003089428A1 (en)	2003-10-30
US20070179187A1 (en)	2007-08-02
SG164279A1 (en)	2010-09-29
SI2065384T1 (en)	2011-05-31
NO330500B1 (en)	2011-05-02
ES2357876T3 (en)	2011-05-03
CY1107184T1 (en)	2012-10-24
US7713999B2 (en)	2010-05-11
KR20040099441A (en)	2004-11-26
ES2297150T3 (en)	2008-05-01
BRPI0309309B1 (en)	2018-09-04
EP2062890B1 (en)	2011-01-05
FR15C0047I1 (en)	2015-08-28
JP4558331B2 (en)	2010-10-06
RU2329264C9 (en)	2009-04-20
LU92759I2 (en)	2015-08-31
EP2062890A1 (en)	2009-05-27
DK2065384T3 (en)	2011-05-02
AR039570A1 (en)	2005-02-23
EP1982984A2 (en)	2008-10-22
EP2065384B1 (en)	2011-01-05
ATE378330T1 (en)	2007-11-15
CN1659162A (en)	2005-08-24
IL164585A0 (en)	2005-12-18
EP1860106A1 (en)	2007-11-28
CA2482858C (en)	2010-11-30
SI1495018T1 (en)	2008-04-30

Publication	Publication Date	Title
CY2015029I1 (en)	2016-04-13	TRICYCLIC THROMBIN RECEPTOR ANTAGONISTS
DK1638969T3 (en)	2009-01-26	CGRP receptor antagonists
IL174538A0 (en)	2006-08-01	Thrombin receptor antagonists
ATE368659T1 (en)	2007-08-15	THROMBIN RECEPTOR ANTAGONISTS
NO20051871D0 (en)	2005-04-18	Opioid receptor antagonists
DK1682142T3 (en)	2012-10-15	M3-muscarinic acetylcholine receptor antagonists
ATE525378T1 (en)	2011-10-15	HIMBACIN ANALOGS AS THROMBIN RECEPTOR ANTAGONISTS
DE602004030930D1 (en)	2011-02-17	MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
DK1720859T3 (en)	2010-04-26	Chemokine receptor antagonists
ZA200702790B (en)	2008-09-25	Thrombin receptor antagonists
DK1711465T3 (en)	2008-03-31	Hydroisoindoline tachykinic receptor antagonists
DE60332816D1 (en)	2010-07-15	NK1 ANTAGONISTS
ATE320254T1 (en)	2006-04-15	CRF RECEPTOR ANTAGONISTS
EP1534736A4 (en)	2006-11-02	NOGO RECEPTOR ANTAGONISTS
SE0003996D0 (en)	2000-11-01	receptor Antagonists

Legal Events

Date	Code	Title	Description
2012-09-24	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: MERCK SHARP AND DOHME CORP Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US
2016-08-22	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: VORAPAXAR ELLER ET FARMASOEYTISK AKSEPTABELT SALT ELLER SOLVAT DERAV; REG. NO/DATE: EU/1/14/976 20150119 Spc suppl protection certif: 2015016 Filing date: 20150709
2020-11-23	MM1K	Lapsed by not paying the annual fees

Date

Code

Title

Description

2012-09-24

CHAD

Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

2016-08-22

SPCG

Granted supplementary protection certificate

Free format text: PRODUCT NAME: VORAPAXAR ELLER ET FARMASOEYTISK AKSEPTABELT SALT ELLER SOLVAT DERAV; REG. NO/DATE: EU/1/14/976 20150119

Spc suppl protection certif: 2015016

Filing date: 20150709

2020-11-23

MM1K

Lapsed by not paying the annual fees